Bryleos
Bryleos is a pre-revenue, clinical-stage therapeutics company developing BRY101, a first-in-class oral NAD+ therapeutic for neurodegenerative diseases of aging and substance use disorder, using its proprietary LathMized™ Green Platform Technology and AI/ML-driven drug discovery.
- Company typePrivate
- Founded2021
- HeadquartersJohnson City, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Bryleos does
Bryleos is a clinical-stage therapeutics company developing interventions for neurological diseases of aging by leveraging NAD+ biology. Its lead asset, BRY101 (also referenced as BNAD101), is described as a first-in-class oral therapeutic designed to modulate multiple hallmarks of aging simultaneously — specifically mitochondrial dysfunction, neuroinflammation, and oxidative stress — rather than acting on a single target. The initial indication set spans neurodegenerative conditions including Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, and FSHD, with a secondary indication in substance use disorder supported by a proof-of-concept study at the Institute for Systems Biology showing a 52% increase in intracellular NAD+ levels within five days.
The company's underlying technology comprises two layers: (1) an AI and machine learning-enabled drug discovery platform positioned to accelerate target identification and development timelines, and (2) the proprietary LathMized™ Green Platform Technology, a manufacturing/process platform that optimizes the bioavailability and stability of molecular entities using waterless, low-energy, and non-toxic processes. Bryleos is privately held, headquartered in Johnson City, Tennessee (legal entity BioNADrx Holdings, Inc.), was founded in 2021, operates with 1–10 employees, and has raised $5 million in seed funding in June 2023 with Eddie Jordan among the backers.
Bryleos is pre-revenue with no approved product, no pricing model, and no disclosed customers. Its business model is the standard clinical-stage therapeutics pathway: develop BRY101 through preclinical and clinical milestones toward regulatory approval, with future commercialization through traditional pharmaceutical distribution (healthcare provider prescriptions and pharmacy dispensing) in the United States. The LathMized™ platform carries optionality for broader application to existing drugs and supplements, but no licensing or partnership revenue has been disclosed to date. The company's GTM motion is therefore entirely upstream — research partnerships, investigator relationships, and investor communications via LinkedIn and the corporate website — until regulatory milestones unlock commercialization.
Bryleos firmographics
Firmographics- Name
- Bryleos
- Legal name
- BioNADrx Holdings, Inc.
- Website
- https://bryleos.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bryleos is a pre-revenue, clinical-stage therapeutics company developing BRY101, a first-in-class oral NAD+ therapeutic for neurodegenerative diseases of aging and substance use disorder, using its proprietary LathMized™ Green Platform Technology and AI/ML-driven drug discovery.
- Ownership category
- akta.pro rank
Where Bryleos is headquartered
LocationHeadquarters
- HQ city
- Johnson City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bryleos business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
Bryleos product offering
Product offeringCore offering
Bryleos is a clinical-stage biopharmaceutical company developing BRY101, a first-in-class oral therapeutic that targets mitochondrial dysfunction, neuroinflammation, and oxidative stress to treat neurodegenerative diseases of aging (Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, FSHD) and substance use disorder. The program is supported by the proprietary LathMized™ Green Platform Technology, which optimizes bioavailability and stability of molecular entities through sustainable, waterless, low-energy manufacturing processes.
Product overview
Bryleos is developing interventions for neurological diseases of aging by leveraging NAD+ therapeutics and advanced technology. The company's lead product is BRY101, a first-in-class oral therapeutic targeting multiple hallmarks of aging including mitochondrial dysfunction, neuroinflammation, and oxidative stress. This is supported by the LathMized™ Green Platform Technology, which optimizes bioavailability and stability of therapeutic compounds using sustainable, waterless processes.
Differentiator
Problem solved
Functional benefit
Products and services
- BRY101
Quantifiable outcome
- 52% increase in intracellular NAD levels within 5 days
Companies that use Bryleos
Customer profileSegments2 records
Ideal customer profiles2 records
Bryleos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Bryleos partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Institute for Systems BiologycoreConducted the proof-of-concept study for BNAD101 showing a 52% increase in intracellular NAD levels within 5 days. Study supports the potential of BNAD101 to treat conditions requiring rapid response, such as addiction.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
Bryleos competitors and assessment
Company assessmentDirect peers
- Elysium Health: Consumer and clinical-stage company built around NAD+ biology and aging biology, developing both supplement and therapeutic NAD+-boosting products — directly comparable mechanism and indication overlap to Bryleos' BRY101.
- Metro International Biotech: Clinical-stage developer of NAD+ precursor therapeutics (e.g., MIB-626) for aging-related and metabolic indications; closest direct mechanistic peer to Bryleos' NAD+ restoration approach.
- ChromaDex: Markets nicotinamide riboside (Niagen) and other NAD+ precursors for consumer health and pharma partnerships; comparable NAD+ mechanism and platform-extension commercial model.
- Annovis Bio: Clinical-stage biotech developing orally delivered small molecules for neurodegenerative diseases (Alzheimer's, Parkinson's), sharing target indications and small-cap clinical-stage profile with Bryleos.
- Amylyx Pharmaceuticals: Commercial/clinical-stage developer of therapeutics for neurodegenerative diseases (ALS, Alzheimer's); directly comparable indication focus and CNS drug-development trajectory.
- Cassava Sciences: Clinical-stage CNS company developing treatments for Alzheimer's disease; comparable small-cap, single-asset neurodegeneration profile to Bryleos.
- Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration and lysosomal biology, with multiple CNS programs; comparable indication focus though at significantly larger scale.
- Cyclerion Therapeutics: Clinical-stage CNS-focused biotech pursuing novel mechanisms for neurological diseases; comparable small-cap, mechanism-driven CNS development profile.
- BioAge Labs: Clinical-stage biotech developing therapeutics that target the biology of aging, including neurodegeneration; directly comparable hallmarks-of-aging therapeutic thesis.
Emerging players
- Neuron23: Early clinical-stage biotech leveraging AI/ML for neuroscience drug discovery with focus on Parkinson's and other neurodegenerative diseases — overlaps Bryleos on both indication and AI-driven discovery approach.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Bryleos social profiles
Digital presenceBryleos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bryleos leadership team
Management profileNumber of profiles
Profiles1 record
Bryleos funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bryleos M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bryleos
What does Bryleos do?
Bryleos is a clinical-stage biopharmaceutical company developing BRY101, a first-in-class oral therapeutic that targets mitochondrial dysfunction, neuroinflammation, and oxidative stress to treat neurodegenerative diseases of aging (Alzheimer's, Parkinson's, ALS, Multiple Sclerosis, FSHD) and substance use disorder. The program is supported by the proprietary LathMized™ Green Platform Technology, which optimizes bioavailability and stability of molecular entities through sustainable, waterless, low-energy manufacturing processes.
Is Bryleos a public or private company?
Bryleos is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bryleos founded?
Bryleos was founded in 2021. It employs 1 to 10 people.
Where is Bryleos based?
Bryleos is headquartered in Johnson City, United States, in the North America region.
Who are Bryleos's main competitors?
Direct peers on record are Elysium Health, Metro International Biotech, ChromaDex, Annovis Bio, Amylyx Pharmaceuticals, Cassava Sciences, Denali Therapeutics, Cyclerion Therapeutics and BioAge Labs. Neuron23 is listed as an emerging player.
Does Bryleos have an API?
No public API is recorded for Bryleos.